GRK3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07952(GRK3 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07952(GRK3 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

GRK3 (G protein-coupled receptor kinase 3), also known as ADRBK2. is a member of the GRK family that regulates signaling of G protein-coupled receptors (GPCRs). It phosphorylates activated GPCRs, promoting receptor desensitization, internalization, and downstream signaling modulation. Primarily expressed in the brain, cardiovascular system, and immune cells, GRK3 plays roles in neurotransmission, cardiac function, and inflammatory responses. Dysregulation of GRK3 is implicated in various pathologies, including bipolar disorder, heart failure, hypertension, and cancer. For instance, reduced GRK3 levels in the prefrontal cortex are linked to mood disorders, while its overexpression in tumors may influence cell proliferation and metastasis.

GRK3 antibodies are essential tools for studying these mechanisms. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to quantify protein expression, assess localization, and explore interactions in cellular or tissue samples. Commercially available GRK3 antibodies are typically raised against specific epitopes (e.g., C-terminal regions) and validated for species cross-reactivity (human, mouse, rat). Researchers rely on these antibodies to investigate GRK3’s role in disease models, drug discovery, and signaling pathway analyses. However, variability in antibody specificity requires careful validation via knockout controls or peptide blocking to ensure accurate results. Overall, GRK3 antibodies are critical for advancing insights into GPCR-related physiology and therapeutic targeting.